Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655824 · ClinicalTrials.gov registry record · Phase 2
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00655824 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 124 participants.
The verdict
NCT00655824, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) . Th e primary purpose of the trial is to evaluate the long-term effectiveness of repeated courses ( a maximum of 9 treatment courses) of ofatumumab in RA patients who previously received ofatumumab or placebo in Trial Hx-CD20-403.
Interventions
- DRUG ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2008-01-01 |
| Est. Completion | 2013-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655824
The ClinicalTrials.gov registry entry for NCT00655824 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ofatumumab is the first listed.
NCT00655824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00655824 about?
NCT00655824 is a clinical study titled "Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403". A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) . Th e primary purpose of the trial is to evaluate the long-term effectiveness of repeated courses ( a maximum of 9 treatment courses) of ofatumuma...
What is the current status of trial NCT00655824?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2008-01-01. Estimated completion is 2013-03-19.
What interventions are being tested in trial NCT00655824?
The interventions under investigation include: ofatumumab (DRUG).
Who is sponsoring clinical trial NCT00655824?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.